{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"France’s biotech ecosystem: science, capital and scale","slug":"france-s-biotech-ecosystem-science-capital-and-scale","published_at":"2026-05-28T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/france-s-biotech-ecosystem-science-capital-and-scale","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/78432452d425c03a67089fed6cc1beb4049361ea17549188bdb0141243930ef5/eyJlcGlzb2RlSWQiOiJmMzI3NTAyZC0yZDA5LTRiNGQtYTM1Zi0xYTJhOWM0ODQxOWMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmExNmI4YTk4M2Q0MGQ1NWRmYjg0MjczL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTI3X18xMS0yNi0xLm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/78432452d425c03a67089fed6cc1beb4049361ea17549188bdb0141243930ef5/eyJlcGlzb2RlSWQiOiJmMzI3NTAyZC0yZDA5LTRiNGQtYTM1Zi0xYTJhOWM0ODQxOWMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmExNmI4YTk4M2Q0MGQ1NWRmYjg0MjczL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTI3X18xMS0yNi0xLm1wMyJ9.mp3","summary":"In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Ksenija Pavletic , Partner and Chief Commercial Officer, Jeito Capital Thierry Laugel , Managing Partner, Kurma Partners Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner a…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1260,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/france-s-biotech-ecosystem-science-capital-and-scale/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/france-s-biotech-ecosystem-science-capital-and-scale.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}